BullishCurve

When reminiscing about the tumultuous landscape of the stock market in 2023, it’s nearly impossible to ignore the meteoric rise of Nvidia (NASDAQ: NVDA) and the unstoppable surge of artificial intelligence (AI) technologies. By the year’s end, Nvidia had ascended to a staggering $500 per …

Read more

As the clock ticks closer to the new year, investors can’t help but marvel at the impressive performance of Wall Street in 2023. The Dow Jones Industrial Average (DJINDICES: ^DJI) hit a historic high, with the benchmark S&P 500 (SNPINDEX: ^GSPC) and innovation-driven Nasdaq Composite …

Read more

Investing in companies capable of advancing and profiting from influential trends can be a life-changing path to wealth creation. Not every stock you buy will go on to be a world-beating success story, but holding just a few big winners over the long term can …

Read more

While isolationism and nationalism appear to be rising themes in global politics, with the investing game, diversity is a core strength, thus boosting the narrative of international stocks. Fundamentally, going abroad for profits may provide risk management. Just like you wouldn’t put all your money …

Read more

The stock market in 2023 witnessed an electrifying surge led by the “Magnificent Seven,” comprising technology giants like Tesla, Nvidia, Apple, Amazon, Meta Platforms, Microsoft, and Alphabet. The collectively awe-inspiring rise of these companies, ranging from 50% to 250%, played a pivotal role in propelling …

Read more

Emerson Electric's recent acquisition of National Instruments has reverberated throughout the business world, causing a ripple effect that has captured the attention of industry experts and investors alike. With the deal valued at an impressive $8.2 billion and receiving approval from both China and the …

Read more

Farmer Brothers, a prominent coffee manufacturer and distributor, recently announced its financial results for the third quarter, which fell short of expectations. The company's GAAP EPS came in at -$0.57, missing expectations by $0.17, and its revenue of $124.2 million also fell short by $9.8 …

Read more

As an investor, I've come across an intriguing statistic that has piqued my curiosity. CytoDyn, a biotech company specializing in innovative therapies, is currently facing a federal indictment. With their former CEO under scrutiny for issuing false statements and misleading documents, the company has found …

Read more